Get the Stockscreener App
8.78
0.23%
-0.06
Actinium Pharmaceuticals Inc stock is currently priced at $8.78, with a 24-hour trading volume of 185.61K.
It has seen a -0.23% decreased in the last 24 hours and a -7.55% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $8.73 pivot point. If it approaches the $9.11 resistance level, significant changes may occur.
Previous Close:
$8.84
Open:
$8.88
24h Volume:
185.61K
Market Cap:
$263.29M
Revenue:
$1.05M
Net Income/Loss:
$-48.82M
P/E Ratio:
-4.8242
EPS:
-1.82
Net Cash Flow:
$-47.49M
1W Performance:
+14.55%
1M Performance:
-7.55%
6M Performance:
+80.00%
1Y Performance:
+0.23%
1D Range:
$8.45
$8.94
52W Range:
$4.00
$9.8599
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Name
Actinium Pharmaceuticals Inc
Sector
Industry
Phone
646-767-3870
Address
275 Madison Avenue, 7th Floor, New York, NY
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-08-22 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-25-22 | Initiated | B. Riley Securities | Buy |
| Nov-05-20 | Initiated | Alliance Global Partners | Buy |
| Dec-06-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-14-17 | Initiated | Maxim Group | Buy |
| Aug-25-16 | Initiated | ROTH Capital | Buy |
| Feb-29-16 | Initiated | H.C. Wainwright | Buy |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Oct-01-14 | Initiated | MLV & Co | Buy |
| Jul-22-14 | Initiated | Canaccord Genuity | Buy |
View All
Actinium Pharmaceuticals Inc Stock (ATNM) Latest News
Actinium Pharmaceuticals Inc Stock (ATNM) Financials Data
Actinium Pharmaceuticals Inc (ATNM) Revenue 2024
ATNM reported a revenue (TTM) of $1.05 million for the quarter ending September 30, 2022.
Actinium Pharmaceuticals Inc (ATNM) Net Income 2024
ATNM net income (TTM) was -$48.82 million for the quarter ending December 31, 2023, a -47.86% decrease year-over-year.
Actinium Pharmaceuticals Inc (ATNM) Cash Flow 2024
ATNM recorded a free cash flow (TTM) of -$47.49 million for the quarter ending December 31, 2023, a -673.67% decrease year-over-year.
Actinium Pharmaceuticals Inc (ATNM) Earnings per Share 2024
ATNM earnings per share (TTM) was -$1.83 for the quarter ending December 31, 2023, a -33.58% decline year-over-year.
About Actinium Pharmaceuticals Inc
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
1.00%
0.95%
Cap:
|
Volume (24h):